Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
JAMA Network Open · 10.03.2025 · 8 (3) · e250380
DOI: 10.1001/jamanetworkopen.2025.0380 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 10.03.2025. Verfasst von Hanmeng Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Antiviral Agents. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
IMPORTANCE Nirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)–associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings. OBJECTIVE To estimate the effectiveness of nirsevimab against medically attended RSV infections in infants and to assess how effectiveness varies by disease severity, dosage, and time since immunization. DESIGN, SETTING, AND PARTICIPANTS This test-negative case-control study utilized inpatient, outpatient, and emergency department data from the Yale New Haven Health System. Nirsevimab-eligible infants who were tested for RSV using polymerase chain reaction between October 1, 2023, and May 9, 2024, were included. Infants with RSV-positive results were cases and infants with RSV-negative results were controls. EXPOSURE Nirsevimab immunization, verified through state immunization registries. MAIN OUTCOMES AND MEASURES Effectiveness was estimated using multivariable logistic regression, adjusting for age, calendar month, and potential confounders. Separate models examined estimated effectiveness by clinical setting, dosage, time since immunization, and severity (defined as needing high-flow oxygen or intensive care unit admission). Broader outcomes were also analyzed, including all-cause LRTI and all-cause LRTI-associated hospitalization. RESULTS The analytic sample included 3090 infants (1722 male [57.3%]; median [IQR] age at testing, 6.7 [3.6-9.7] months), with 680 (22.0%) RSV-positive cases and 2410 (78.0%) RSV-negative controls. Nirsevimab uptake was 10.7% (330 patients), with 21 RSV-positive cases and 309 RSV-negative controls immunized. Adjusted effectiveness was 68.4% (95% CI, 50.3%-80.8%) against medically attended RSV infection, 61.6% (95% CI, 35.6%-78.6%) against outpatient visits, and 80.5% (95% CI, 52.0%-93.5%) against hospitalizations. The highest estimated effectiveness (84.6%; 95% CI, 58.7%-95.6%) was observed against severe RSV disease. Although estimated effectiveness against RSV infections declined from 79.3% (95% credible interval, 63.4%-90.6%) at 2 weeks postimmunization to 54.8% (95% credible interval, 16.3%-74.7%) at 14 weeks postimmunization, it remained significant. Estimated effectiveness did not vary substantially by dosage. During peak RSV season, nirsevimab appeared effective against all-cause LRTI (49.4%; 95% CI, 10.7%-72.9%) and all-cause LRTI-associated hospitalizations (79.1%; 95% CI, 27.6%-94.9%). From February to May 2024, when most LRTIs were caused by other viruses, its estimated effectiveness against these broader outcomes was negligible. CONCLUSIONS AND RELEVANCE In this case-control study, nirsevimab provided substantial protection against RSV-associated outcomes. These findings support its continued use and provide evidence that may help boost public confidence in the immunization program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut.
- Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of Medicine, New Haven, Connecticut.
- Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
- Department of Biostatistics, Section of Health Informatics, Yale School of Public Health, New Haven, Connecticut.
- Department of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, Connecticut.
Förderung
- NIAID NIH HHS
Zitieren
APA
Xu, H., Aparicio, C., Wats, A., Araujo, B. L., Pitzer, V. E., Warren, J. L., Shapiro, E. D., Niccolai, L. M., Weinberger, D. M., & Oliveira, C. R. (2025). Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open, 8(3), e250380. https://doi.org/10.1001/jamanetworkopen.2025.0380
Vancouver
Xu H, Aparicio C, Wats A, Araujo BL, Pitzer VE, Warren JL, et al. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open. 2025;8(3):e250380. doi:10.1001/jamanetworkopen.2025.0380
BibTeX
@article{Xu2025,
author = {Xu, Hanmeng and Aparicio, Camila and Wats, Aanchal and Araujo, Barbara L and Pitzer, Virginia E and Warren, Joshua L and Shapiro, Eugene D and Niccolai, Linda M and Weinberger, Daniel M and Oliveira, Carlos R},
title = {Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {3},
pages = {e250380},
doi = {10.1001/jamanetworkopen.2025.0380}
}
EUVIMED